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Electronic cigarettes have exploded on to global markets over
the past decade and in the process have generated some strongly
polarised views.1-3 Some believe that e-cigarettes are a disruptive
technology that could consign tobacco smoking to history; others
think that they are a distraction from core public health aims of
eradicating all nicotine use and a tobacco industry ploy to
perpetuate smoking and undermine international tobacco control
treaties. This article summarises the findings of a new report
by the Royal College of Physicians (RCP) on the role of
e-cigarettes in tobacco harm reduction.4
Smoking: the biggest avoidable cause of
harm to health
There are few practices more harmful to individuals or society
than smoking. Life expectancy is reduced by around three
months for every year of smoking after the age of 35.5 6 Smoking
impairs quality of life through disease and poverty,7 causes
substantial harm to others, particularly young people and unborn
babies,8 and imposes a heavy financial and opportunity cost on
wider society.7Despite declining prevalence over recent decades
there are still nearly nine million smokers in the UK, a high
proportion of whom are from among the most disadvantaged
in our society.4 Smoking is still the largest avoidable cause of
premature death, disability, and social inequalities in health in
the UK.
Harm reduction: part of a comprehensive
approach to smoking prevention
From its groundbreaking first report on smoking and health in
1962,9 which established the pillars of global tobacco control
policy,10-12 the RCP has advocated comprehensive strategies to
prevent harm caused to individuals and society by tobacco
smoking. However, current policy levers have proved more
effective in preventing uptake of smoking than in helping
established smokers to quit. It is primarily for this reason that
the RCP has advocated policies that encourage and enable
smokers to switch to less harmful sources of nicotine.13 14
Separating toxicity from addiction
Writing in The BMJ in 1976,Mike Russell observed that “people
smoke for nicotine but die from the tar.”15 Nicotine is most
addictive when delivered to the brain quickly and in high doses.
Cigarette design and the composition of tobacco have been
engineered to deliver high doses of nicotine at rates that exceed
even those achieved by intravenous injection. However, even
at the doses absorbed from cigarettes nicotine causes little if
any harm: it is the carcinogens, carbonmonoxide, and thousands
of other toxins in tobacco smoke that kill. This means that health
harms from smoking can be avoided by replacing cigarettes
with a less toxic source of nicotine.
This principle underpins evidence based guidance on tobacco
harm reduction published by the National Institute for Health
and Care Excellence (NICE) in 2013,16 17 which recommends
complete, or failing that partial (known as dual use), replacement
of smoked tobacco with medicinally licensed nicotine
replacement therapies for smokers who are otherwise unable or
unwilling to quit. Those who achieve complete substitution
achieve much the same in health terms as those who quit all
smoking and nicotine use. People who adopt dual use gain
relatively little direct health benefit but are much more likely
to be able to quit smoking in the future.16 17However, for various
reasons, including the relatively low doses or rates of nicotine
delivery that nicotine replacement therapies provide and their
failure to reproduce many of the behavioural and sensory
components of tobacco smoking, many smokers who try nicotine
replacement therapy revert to smoking.
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The emergence of e-cigarettes has revolutionised the choice of
nicotine products available to smokers. Early devices were
designed to resemble cigarettes, were of variable quality, and
delivered relatively low doses of nicotine, but some newer
designs, which are generally larger and look less like cigarettes,
are able to deliver sufficient nicotine to replicate at least the
venous (if not arterial) nicotine levels achieved by smoking.
E-cigarettes also reproducemany of the behavioural and sensory
characteristics of smoking and benefit from perception as a
consumer rather than medicinal product. E-cigarettes have
already overtaken nicotine replacement therapies as the primary
aid used in attempts to quit smoking in the UK: an estimated
2.6 million people currently use e-cigarettes in the UK, almost
all of whom are or have been smokers, and one third of whom
no longer smoke.1As e-cigarette technology advances, nicotine
delivery kinetics are likely to grow closer to those of cigarettes,
making them increasingly satisfying to smokers but also
probably increasing their addictiveness.
E-cigarettes: harm reduction or
exacerbation?
E-cigarettes have encountered significant scepticism as well as
support from the UK and international health community. Some
of the many arguments advanced against their use to prevent
harm from smoking have been that their long term health effects
are not clearly understood; that the products may, through dual
use, sustain smoking among smokers whowould otherwise have
quit; that they may attract young people who would not
otherwise have used nicotine to become regular users, and in
due course to become smokers (gateway effect); that they
re-establish the act of inhaling nicotine as something that is
acceptable in public and hence promote smoking
(renormalisation); that they divert smokers who are motivated
to quit away from evidence based smoking cessation treatment
services; that they will undermine the benefits of smoke-free
legislation; and that they will be used by the tobacco industry
to present itself as a part of the solution to, rather than the cause
of, the smoking epidemic.
The RCP report4 explores evidence relating to all of the above
concerns, and provides reassurance on almost all of them. The
report argues that e-cigarettes are unlikely to be harmless, and
that long term use is likely to be associated with long term
sequelae, including an increased risk of chronic obstructive
pulmonary disease, lung cancer, possibly cardiovascular disease,
and some other long term conditions associated with smoking.
However, the magnitude of this risk is likely to be very small
in relation to that from tobacco smoke, and the hazard to health
arising from long term vapour inhalation from the e-cigarettes
available today is unlikely to exceed 5% of the harm from
smoking tobacco.4
Among adults in the UK, e-cigarette use is almost entirely
limited to those who are or have been smokers, in most cases
as a means to cut down or quit smoking. Dual use of electronic
and tobacco cigarettes is common, but there is no evidence that
this has reduced the number of smokers who quit; nor are there
grounds to suspect that the effect of dual use of tobacco and
e-cigarettes will differ from dual use of nicotine replacement
therapy,16 17 which increases the likelihood of quitting. Surveys
of teenagers in the UK indicate that while many try e-cigarettes
once or twice, repeated use is almost entirely limited to those
who are already experimenting with tobacco, with no evidence
of substantial progression to smoking.4
The report also finds no grounds to suspect that use of
e-cigarettes renormalises smoking, or that use where smoking
is prohibited represents a significant hazard to health. It
concludes that the availability of e-cigarettes is unlikely to be
a major factor in the recent decline in number of smokers
accessing stop smoking services,18 which is more likely to have
arisen from reductions in funding for antismoking media
campaigns and smoking cessation services. Observational data
indicate that of smokers who try to quit without accessing stop
smoking services, those who use e-cigarettes are around 50%
more likely to succeed than those who do not (or those who use
nicoting replacement therapies bought over the counter).
However, smokers who access stop smoking services are two
to three times more likely to succeed,4 indicating that
encouraging e-cigarette users to access the additional support
provided by stop smoking services remains important.
Tobacco industry
The tobacco industry’s acquisition of many formerly
independent e-cigarette producers and importers is a cause for
concern. The continued aggressive marketing of cigarettes,
including to children, as well as lobbying and legal challenges
to tobacco control measures, make it clear that the global
tobacco industry has no serious interest in reducing the harm it
causes. The industry is therefore likely to try to exploit
e-cigarettes to enhance its core business of selling tobacco.
Restrictions on e-cigarette advertising required by the European
Union Tobacco Products Directive, to be implemented in May
2016, go some way towards alleviating these concerns. In
addition article 5.3 of the WHO Framework Convention on
Tobacco Control provides a clear framework for governments
to protect tobacco control policy development from industry
interference.19
Regulating to promote health
To date, e-cigarettes have been regulated in the UK as general
consumer products, with additional restrictions on advertising
and minimum age of sale, but from May 2016 the EU directive
will impose new restrictions. The requirement that the content
of e-cigarette solutions and vapour emissions are reported to a
designated competent authority (the Medicines and Healthcare
Products Regulatory Agency in the UK), should help to raise
standards in delivery and purity profiles. However, the directive
will also impose limits on total nicotine content, which may
diminish the effectiveness of e-cigarettes as smoking substitutes,
and require health warnings on e-cigarette packs highlighting
the risks of nicotine, which may discourage use. These
requirements will not apply to products licensed as medicines,
but manufacturers are likely to continue to be discouraged from
pursuing medicines licensing by the high costs and delays that
the process involves. Achieving the right balance of regulation
for e-cigarettes is not easy: too much regulation can stifle
innovation and reduce choice for smokers, while too little leaves
smokers exposed to products that are ineffective, unduly
hazardous, or both. It remains to be seen whether the directive
inhibits or promotes the use of e-cigarettes for harm reduction.
Conclusions
The evidence summarised in the RCP report4 shows that
e-cigarettes have so far been beneficial to UK public health,
both at individual and population level, by providing smokers
with a viable alternative to tobacco smoking. While it is
important to recognise that e-cigarettes are not hazard free, the
primary comparator for these hazards is the substantially greater
risk presented by obtaining nicotine from tobacco smoke.
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Patterns of use and health impacts of electronic and tobacco
cigarettes must continue to be monitored closely, and remedial
measures applied promptly to deal with any changes or trends
that seem counterproductive to health. It is also important that
health professionals communicate the risks and benefits of
electronic and tobacco cigarettes to smokers, both in practice
and through the academic and popular media, objectively and
dispassionately, to redress the growing misconception among
smokers that these products are similarly harmful.20 E-cigarettes
and other non-tobacco nicotine products offer the potential
radically to reduce harm from smoking in our society. This is
an opportunity that should be managed and taken.
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Key messages
Smoking is the biggest avoidable cause of death, disability, and health inequalities in the UK
The hazard to health arising from long term use of e-cigarettes is unlikely to exceed 5% of the harm from smoking tobacco
Experience in the UK suggests that e-cigarettes are more popular with smokers than other non-tobacco nicotine products and are being
used almost entirely by smokers who want to cut down or quit smoking
E-cigarettes represent an important means to reduce the harm to individuals and society from tobacco use
E-cigarettes should continue to be supported by government and promoted as a tobacco harm reduction strategy
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